PLX: First Quarter Update [Yahoo! Finance]
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: Yahoo! Finance
Protalix Biotherapeutics, Inc. (NYSE:PLX) announced first quarter 2024 financial and operational results in a May 10th, 2024 press release and in the filing of Form 10-Q . The reports were followed by a conference call which discussed recent achievements, regulatory updates and financial performance. Since the beginning of the year, with respect to Elfabrio (PRX-102) partner Chiesi has continued its commercialization activities, obtained additional approvals and launched new studies for a pediatric indication and for approval in Japan. Revenues for 1Q:24 were $3.7 million, which consisted almost entirely of product sales which produced a net loss of ($4.6) million or ($0.06) per share. Financial results for the quarter ending March 31st, 2024, compared to prior year comparable period: ? Revenues were $3.7 million, down 61% from $9.6 million on lower revenues from both Pfizer and Brazil. Research and development revenues were also down sharply as responsibility for further devel
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024PR Newswire
- Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the FirmBusiness Wire
- Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024GlobeNewswire
PLX
Earnings
- 8/14/24 - Miss
PLX
Sec Filings
- 10/25/24 - Form SC
- 10/25/24 - Form 8-K
- 9/24/24 - Form 4
- PLX's page on the SEC website